IN2014CN03749A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN03749A IN2014CN03749A IN3749CHN2014A IN2014CN03749A IN 2014CN03749 A IN2014CN03749 A IN 2014CN03749A IN 3749CHN2014 A IN3749CHN2014 A IN 3749CHN2014A IN 2014CN03749 A IN2014CN03749 A IN 2014CN03749A
- Authority
- IN
- India
- Prior art keywords
- compositions
- methods compounds
- symptom
- animal
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided herein are methods compounds and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods compounds and compositions are useful to treat prevent delay or ameliorate metabolic disease for example diabetes or a symptom thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161551378P | 2011-10-25 | 2011-10-25 | |
PCT/US2012/061984 WO2013063313A1 (en) | 2011-10-25 | 2012-10-25 | Antisense modulation of gccr expression |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03749A true IN2014CN03749A (en) | 2015-09-25 |
Family
ID=48168513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3749CHN2014 IN2014CN03749A (en) | 2011-10-25 | 2012-10-25 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8901098B2 (en) |
EP (1) | EP2771463A4 (en) |
JP (1) | JP2015501155A (en) |
KR (1) | KR20140084232A (en) |
CN (1) | CN103906838A (en) |
AU (2) | AU2012328680A1 (en) |
BR (1) | BR112014009790A2 (en) |
CA (1) | CA2853373A1 (en) |
HK (1) | HK1201555A1 (en) |
IL (1) | IL232183A0 (en) |
IN (1) | IN2014CN03749A (en) |
MX (1) | MX350944B (en) |
RU (1) | RU2014119787A (en) |
WO (1) | WO2013063313A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE050394T2 (en) | 2013-05-01 | 2020-11-30 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating apolipoprotein (a) expression |
ES2812099T3 (en) | 2014-05-01 | 2021-03-16 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating growth hormone receptor expression |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3722424A1 (en) * | 2015-04-16 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
WO2017059205A1 (en) * | 2015-09-30 | 2017-04-06 | Ionis Pharmaceuticals, Inc. | Combination therapy |
US10083668B2 (en) | 2016-03-09 | 2018-09-25 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device, display device, and electronic device |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
UA128786C2 (en) | 2017-10-20 | 2024-10-23 | Дайсерна Фармасьютикалз, Інк | Methods for treating hepatitis b infection |
CA3086409A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
WO2020167593A1 (en) | 2019-02-12 | 2020-08-20 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for inhibiting expression of cyp27a1 |
CN109680095A (en) * | 2019-02-25 | 2019-04-26 | 广西中医药大学 | A kind of SSR Primer composition and its cultivar identification method for identifying picria fel tarrae kind |
US20220170025A1 (en) | 2019-04-04 | 2022-06-02 | Dicerna Pharmaceuticals Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
TW202200163A (en) | 2020-03-18 | 2022-01-01 | 美商戴瑟納製藥股份有限公司 | Compositions and methods for inhibiting angptl3 expression |
MX2023001541A (en) | 2020-08-04 | 2023-03-08 | Dicerna Pharmaceuticals Inc | Systemic delivery of oligonucleotides. |
US20240084309A1 (en) | 2020-08-04 | 2024-03-14 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting plp1 expression |
TW202221120A (en) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | Compositions and methods for the treatment of metabolic syndrome |
AU2021320550A1 (en) | 2020-08-05 | 2023-02-16 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting |
KR20230104880A (en) | 2020-10-08 | 2023-07-11 | 다이서나 파마수이티컬, 인크. | Selective delivery of oligonucleotides to glial cells |
EP4323518A2 (en) | 2021-04-12 | 2024-02-21 | Boehringer Ingelheim International GmbH | Compositions and methods for inhibiting ketohexokinase (khk) |
CN117120613A (en) | 2021-04-14 | 2023-11-24 | 迪克纳制药公司 | Compositions and methods for modulating PNPLA3 expression |
MX2023012086A (en) | 2021-04-19 | 2023-10-25 | Novo Nordisk As | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression. |
IL308418A (en) | 2021-05-28 | 2024-01-01 | Novo Nordisk As | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression |
WO2023027759A1 (en) | 2021-08-25 | 2023-03-02 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting αlpha-1 antitrypsin expression |
CA3235941A1 (en) | 2021-12-01 | 2023-06-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating apoc3 expression |
US20230374522A1 (en) | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
WO2023220349A1 (en) | 2022-05-12 | 2023-11-16 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting mapt expression |
AR129312A1 (en) | 2022-05-13 | 2024-08-14 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING SNCA EXPRESSION |
TW202400193A (en) | 2022-06-24 | 2024-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression |
TW202430637A (en) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3 targeting oligonucleotides and uses thereof |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
EP0318500A4 (en) | 1986-08-01 | 1989-12-22 | Genetics Inst | High level inducible expression of heterologous genes. |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
JP3220180B2 (en) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
JPH08504559A (en) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | Motor system with individually controlled redundant windings |
JP3351476B2 (en) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | Phospholipid derivatives and liposomes containing the same |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
US6248724B1 (en) | 1997-09-25 | 2001-06-19 | University Of Florida | Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use |
US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
US20030203862A1 (en) | 1998-03-26 | 2003-10-30 | Miraglia Loren J. | Antisense modulation of MDM2 expression |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US6821724B1 (en) | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
DK1163254T3 (en) | 1999-02-26 | 2008-06-09 | Univ British Columbia | TRPM-2 antisense treatment |
GB9907048D0 (en) | 1999-03-27 | 1999-05-19 | Karobio Ab | Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders |
KR100782896B1 (en) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-Ribo-LNA analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
CA2393045A1 (en) | 1999-12-07 | 2001-06-14 | Sumitomo Chemical Co., Ltd. | Mutant er.alpha. and test systems for transactivation |
US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
GB0008936D0 (en) | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Vectors |
US6649341B1 (en) | 2000-04-19 | 2003-11-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Human glucocorticoid receptor 1A promoter and splice variants |
US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US7227007B2 (en) | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
WO2003070888A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
WO2002096943A1 (en) | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
US20030092616A1 (en) | 2001-05-25 | 2003-05-15 | Akio Matsuda | STAT6 activation gene |
CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
JP2005516586A (en) | 2001-07-20 | 2005-06-09 | ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ | Reagents and methods for identifying gene targets for the treatment of cancer |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
AU2003214882A1 (en) | 2002-01-23 | 2003-09-02 | Mayo Foundation For Medical Education And Research | Polycystic kidney disease nucleic acids and proteins |
AU2003213054A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2003265184A (en) | 2002-03-18 | 2003-09-24 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | Method for examining effectiveness of glucocorticoid preparation in examinee |
DE60327618D1 (en) | 2002-03-27 | 2009-06-25 | Aegera Therapeutics Inc | ANTISENSE NUCLEOBASIS AND ITS APPLICATIONS AGAINST IAP |
EP1501930A2 (en) | 2002-04-05 | 2005-02-02 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
EP1534728A4 (en) | 2002-05-20 | 2005-10-26 | Pharmacia Corp | Antisense modulation of glucocorticoid receptor expression |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP4429906B2 (en) | 2002-08-16 | 2010-03-10 | レクサーン・コーポレイション | Use of antisense oligonucleotides to suppress Akt-1 expression |
AU2003298556A1 (en) | 2002-08-19 | 2004-05-04 | Regulome Corporation | Functional sites |
CA2494764C (en) | 2002-08-21 | 2013-04-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
CA2505330A1 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
CA2507469C (en) | 2002-11-25 | 2015-04-28 | Den Kgl. Veterinaer-Og Landbohojskole | Porcine polymorphisms and methods for detecting them |
WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
DK1661905T3 (en) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Novel N-O cross-linking synthetic nucleic acids |
US20050142581A1 (en) | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
CA2538252C (en) | 2003-09-18 | 2014-02-25 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
DE602004027163D1 (en) | 2003-12-23 | 2010-06-24 | Santaris Pharma As | OLIGOMER COMPOUNDS FOR MODULATING BCL-2 |
EP2363480A3 (en) | 2004-01-20 | 2015-10-07 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US7919472B2 (en) | 2004-09-17 | 2011-04-05 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
US20070154896A1 (en) | 2005-02-11 | 2007-07-05 | International Business Machines Corporation | System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences |
JP2006320271A (en) * | 2005-05-20 | 2006-11-30 | Tokyo Institute Of Technology | Method for evaluation of binding between low molecular weight compound with protein |
CA2623772A1 (en) | 2005-09-19 | 2007-03-29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Modulation of glucocorticoid receptor expression |
KR101304071B1 (en) | 2006-01-27 | 2013-09-06 | 아이시스 파마수티컬즈 인코포레이티드 | 6-modified bicyclic nucleic acid analogs |
US9045754B2 (en) | 2006-05-05 | 2015-06-02 | Isis Pharmaceuticals, Inc. | Short antisense compounds with gapmer configuration |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US8278426B2 (en) | 2007-06-08 | 2012-10-02 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
DK2176280T4 (en) | 2007-07-05 | 2015-07-20 | Isis Pharmaceuticals Inc | 6-Disubstituerede bicykliske nukleinsyreanaloge |
-
2012
- 2012-10-25 EP EP12843053.5A patent/EP2771463A4/en not_active Withdrawn
- 2012-10-25 AU AU2012328680A patent/AU2012328680A1/en not_active Abandoned
- 2012-10-25 US US13/660,885 patent/US8901098B2/en not_active Expired - Fee Related
- 2012-10-25 BR BR112014009790A patent/BR112014009790A2/en active Search and Examination
- 2012-10-25 CA CA2853373A patent/CA2853373A1/en not_active Abandoned
- 2012-10-25 CN CN201280051744.5A patent/CN103906838A/en active Pending
- 2012-10-25 JP JP2014539019A patent/JP2015501155A/en active Pending
- 2012-10-25 MX MX2014005067A patent/MX350944B/en active IP Right Grant
- 2012-10-25 RU RU2014119787/10A patent/RU2014119787A/en not_active Application Discontinuation
- 2012-10-25 IN IN3749CHN2014 patent/IN2014CN03749A/en unknown
- 2012-10-25 KR KR1020147013594A patent/KR20140084232A/en not_active Application Discontinuation
- 2012-10-25 WO PCT/US2012/061984 patent/WO2013063313A1/en active Application Filing
-
2014
- 2014-04-22 IL IL232183A patent/IL232183A0/en unknown
- 2014-10-24 US US14/523,751 patent/US9567587B2/en not_active Expired - Fee Related
-
2015
- 2015-02-27 HK HK15101964.3A patent/HK1201555A1/en unknown
-
2018
- 2018-05-21 AU AU2018203564A patent/AU2018203564A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8901098B2 (en) | 2014-12-02 |
US9567587B2 (en) | 2017-02-14 |
JP2015501155A (en) | 2015-01-15 |
AU2018203564A1 (en) | 2018-06-07 |
CN103906838A (en) | 2014-07-02 |
US20130150425A1 (en) | 2013-06-13 |
RU2014119787A (en) | 2015-12-10 |
BR112014009790A2 (en) | 2018-05-15 |
HK1201555A1 (en) | 2015-09-04 |
MX350944B (en) | 2017-09-26 |
WO2013063313A1 (en) | 2013-05-02 |
IL232183A0 (en) | 2014-06-30 |
US20150141493A1 (en) | 2015-05-21 |
MX2014005067A (en) | 2014-08-22 |
CA2853373A1 (en) | 2013-05-02 |
EP2771463A4 (en) | 2015-09-09 |
AU2012328680A1 (en) | 2014-05-01 |
KR20140084232A (en) | 2014-07-04 |
EP2771463A1 (en) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03749A (en) | ||
IN2014CN02736A (en) | ||
MX343559B (en) | Modulation of transthyretin expression. | |
IL266001B (en) | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease | |
MX353152B (en) | Modulation of huntingtin expression. | |
MY162715A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
EP3489360A3 (en) | Modulation of nuclear-retained rna | |
MX2016008462A (en) | Modulation of angiopoietin-like 3 expression. | |
MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
WO2012174476A3 (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
EP2766474A4 (en) | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | |
EP2739286A4 (en) | Bile acid recycling inhibitors for treatment of pancreatitis | |
EP2701742A4 (en) | Compositions and method for treating autoimmune diseases | |
MX2014004074A (en) | Methods of treating liver conditions using notch2 antagonists. | |
HK1201771A1 (en) | Compositions and methods for treating alzheimers disease | |
CL2014000557A1 (en) | Improved antioxidant composition for animal feed and animal feed constituents; and method to improve said composition. | |
HRP20180687T1 (en) | Compositions and methods for treating celiac sprue disease | |
UY34070A (en) | METHOD AND COMPOSITION FOR SEED TREATMENT. | |
EA201500752A1 (en) | METHOD OF TREATMENT OF DISEASES | |
HK1184642A1 (en) | Date pit composition for the treatment of animals | |
LU91877B1 (en) | Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy | |
EP2702997A4 (en) | Method and composition for enhancing target cells uptake of therapeutic agents | |
HUP1100535A2 (en) | Pharmaceutical composition for enhancement of stem cell treatment | |
UA64793U (en) | Method for simulation of acute sialadenite |